免疫亲和蛋白家族的新成员FKBPL的研究进展

Research Progress on FKBPL,A New Member of Immune Affinity Protein Family

FKBPL是一种新型的免疫亲和蛋白,临床被用于众多疾病治疗中。FKBPL不仅能够使肿瘤的生长与转移得到有效抑制,亦可调节雌激素受体信号,对于内分泌治疗的反应具有决定性作用。除此之外,FKBPL可调节有关心脏功能障碍的病理血管生成状况,将其用于妊娠期糖尿病患者治疗中,通过下调处理,利于患者血管生成、内皮功能的有效改善。FKBPL-CD44通路在子痫前期风险分层和间充质干细胞治疗中同样发挥关键性作用。基于此,文章将FKBPL作为主要研究内容,重点阐述其作为免疫亲和蛋白治疗临床疾病的相关研究进展,希望有所帮助。

FKBPL is a novel immune affinity protein which has been clinically applied in treatment of numerous diseases.It can inhibits tumor growth and metastasis effectively,regulate estrogen receptor signaling,which plays decisive role in response to endocrine therapy.Moreover,FKBPL can regulate pathological angiogenesis of cardiac dysfunction,which can be beneficial to effective improvement of angiogenesis and endothelial function in treatment of diabetes patients during pregnancy through down-regulation.FKBPL-CD44 pathway also plays a crucial role in risk stratification of preeclampsia and mesenchymal stem cell therapy.Based on this,the article related research progress of FKBPL as immunoaffinity protein in treatment of clinical diseases,hope to be helpful.